预约演示
更新于：2025-12-12
Lidocaine/Prilocaine
复方利多卡因
更新于：2025-12-12
概要
基本信息
在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1992-12-30), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C27H42N4O2 |
InChIKeyWZSPWMATVLBWRS-UHFFFAOYSA-N |
CAS号101362-25-8 |
关联
284
项与 复方利多卡因 相关的临床试验CTRI/2025/09/095420
Optimizing Palatal Anesthesia in Children: EMLA Cream with Different Drug Delivery Systems
CTIS2025-522168-34-00
BRECHE : Efficacy of sphenopalatine block compared to blood patch in the management of post-dural puncture syndrome.
CTR20254376
利丙双卡因乳膏在中国健康受试者中空腹给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验临床研究方案
100 项与 复方利多卡因 相关的临床结果
登录后查看更多信息
100 项与 复方利多卡因 相关的转化医学
登录后查看更多信息
100 项与 复方利多卡因 相关的专利（医药）
登录后查看更多信息
1,023
项与 复方利多卡因 相关的文献（医药）2025-12-01ANNALS OF VASCULAR SURGERY
Comparison of Wound Healing after Bypass Surgery versus Endovascular Therapy for Dialysis-Dependent or Independent Patients with Chronic Limb-Threatening Ischemia and Inframalleolar Disease: A Retrospective Cohort Study
Article
作者: Nakayama, Ken ; Kurose, Shun ; Yamaoka, Terutoshi ; Matsuda, Daisuke ; Yoshizumi, Tomoharu ; Yoshino, Shinichiro ; Mii, Shinsuke ; Guntani, Atsushi ; Morisaki, Koichi ; Inoue, Kentaro
BACKGROUND:
Patients with chronic limb-threatening ischemia (CLTI) and inframalleolar (IM) P1 disease present a substantial challenge, and the impact of dialysis on revascularization outcomes remains unclear. This study aimed to compare wound healing and limb salvage after bypass surgery (BSX) and endovascular therapy (EVT) in dialysis-dependent and dialysis-independent patients with CLTI and IM P1.
METHODS:
We retrospectively analyzed the multicenter data from patients undergoing infrainguinal revascularization for CLTI with IM P1 between 2015 and 2023. Patients were categorized into 4 cohorts based on dialysis dependence and Wound, Ischemia, and foot Infection (WIfI) stages 3 and 4.
RESULTS:
We reviewed collected data from 690 patients with CLTI and IM P1. After propensity score matching, we analyzed 42 dialysis-dependent patients with WIfI 3, 54 dialysis-dependent patients with WIfI 4, 41 dialysis-independent patients with WIfI 3, and 56 dialysis-independent patients with WIfI 4. In the dialysis-dependent cohort, BSX was associated with significantly higher wound healing rates than EVT in WIfI stages 3 and 4. In the dialysis-independent cohort, no significant difference in wound healing was observed between the groups in either WIfI stage. Overall survival did not significantly differ between BSX and EVT in any subgroup.
CONCLUSION:
In summary, BSX may lead to better wound healing than EVT in dialysis-dependent patients with IM P1 disease and WIfI stages 3 and 4. No significant differences were observed between treatment strategies in dialysis-independent patients. Thus, BSX might be a preferable revascularization strategy in selected dialysis-dependent patients, although prospective studies are needed to confirm this result.
2025-11-02Pain Management
Effect of dual direct and alternating currents on pain induced by blood sampling and intramuscular injection processes
Article
作者: Ezzati, Ebrahim ; Mohammadi, Saeed ; Mahooti, Roghaye ; Kavyannejad, Rasoul
OBJECTIVE:
This study investigates the effects of cathodal, anodal, and intermittent electrical stimulation on pain intensity associated with arterial blood sampling, venous blood sampling, and intramuscular injection.
METHODS:
In a triple-blind clinical trial, 160 patients requiring arterial, venous blood sampling, and intramuscular injection were randomly divided into four groups. Three intervention groups received 5 mA anodal, cathodal direct, or alternating currents during the procedure, while the control group received only a topical eutectic mixture of local anesthetics (EMLA). Pain intensity was measured using the visual analog scale (VAS) immediately after the procedure, while procedure duration, number of attempts, and heart rate changes were recorded as secondary outcome.
RESULTS:
All forms of electrical stimulation significantly reduced procedural pain compared to EMLA. Cathodal direct current demonstrated the greatest analgesic effect, with mean VAS score reductions of 2-3 points across all procedures. The time required for arterial blood sampling in the cathodal group was significantly less than with EMLA, while no difference was observed in the procedure time and frequency of attempts in other processes. Furthermore, electrical stimulation groups, particularly the cathodal mode, exhibited lower post-procedure heart rates, suggesting attenuated physiological stress responses.
CONCLUSION:
We found that applying electric currents during the procedure reduces the pain of blood sampling or injections. The greatest analgesia was observed with cathodal direct current stimulation compared to other groups.
CLINICAL TRIAL REGISTRATION:
Date of registration: 27 January 2024. Clinical Trials.gov Identifier: IRCT20240123060780N1. URL: https://irct.behdasht.gov.ir/trial/75119.
2025-11-01VETERINARY ANAESTHESIA AND ANALGESIA
A comparison of a transdermal eutectic lidocaine/prilocaine cream and subcutaneous lidocaine injection prior to jugular vein catheterization in horses: a randomized crossover study
Article
作者: Stewart, Allison ; Rainger, Joanne ; Woldeyohannes, Solomon ; Goodwin, Wendy ; Zedler, Steven ; Amiet, Biancia
OBJECTIVE:
To compare horses' aversive behavioural responses to the application of 5% prilocaine/lidocaine eutectic mixture of local anaesthetics (EMLA) cream versus subcutaneous infiltration of 2% lidocaine, followed by jugular vein catheterization.
STUDY DESIGN:
Blinded, randomized study.
ANIMALS:
A group of 26 university-owned research horses.
METHODS:
Each horse received both treatments at opposite jugular sites with ≥ 12 hours between procedures. One randomly assigned jugular site received 1 g cm-2 of 5% EMLA cream 60 minutes before catheterization, while the contralateral site received 1.5 mL of 2% lidocaine subcutaneously 15 minutes prior. A 14 gauge catheter was introduced percutaneously and maintained for 20 minutes. A total of four blinded evaluators scored aversive behaviours during treatment application and catheterization using a simple descriptive scale (SDS). Treatment sites were assessed for erythema, blanching, or pain immediately after application and at 20 minutes and 24 hours post-catheter removal. Stratified multivariate Mann-Whitney U tests compared SDS values with significance at p < 0.05.
RESULTS:
Horses showed significantly lower SDS scores during EMLA application versus lidocaine injection (0.3 ± 0.3 and 0.5 ± 0.4, respectively; p = 0.012). However, during catheterization, horses treated with lidocaine had lower SDS scores than those treated with EMLA (0.4 ± 0.4 and 0.8 ± 0.5, respectively; p = 0.006), although this difference was not significant when corrected for catheter placement side (p = 0.077). Neither treatment caused adverse effects at application sites.
CONCLUSIONS AND CLINICAL RELEVANCE:
The application of 5% EMLA cream was well tolerated in horses and may provide an alternative to subcutaneous infiltration of lidocaine prior to jugular vein catheterization in horses.
100 项与 复方利多卡因 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 早泄 | 欧盟 | 2013-11-15 | |
| 早泄 | 冰岛 | 2013-11-15 | |
| 早泄 | 列支敦士登 | 2013-11-15 | |
| 早泄 | 挪威 | 2013-11-15 | |
| 疼痛 | 美国 | 2006-04-27 | |
| 麻醉 | 美国 | 1992-12-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 72 | (Emla-cream) | 窪製鬱觸憲鏇製鬱餘獵(憲製範製齋獵衊選顧廠) = 鏇繭糧壓齋艱糧網願糧 鹽壓夢顧願鹹襯醖糧鹽 (夢網獵構範鹽簾壓繭齋, 淵構膚製廠製醖鹹築築 ~ 鏇簾鹹獵壓網蓋願淵製) 更多 | - | 2025-10-23 | ||
Miniderm cream (Miniderm Cream) | 窪製鬱觸憲鏇製鬱餘獵(憲製範製齋獵衊選顧廠) = 窪鏇築壓獵鏇廠蓋鹹構 鹽壓夢顧願鹹襯醖糧鹽 (夢網獵構範鹽簾壓繭齋, 餘齋憲繭淵構襯憲鬱構 ~ 廠衊鑰壓壓壓願廠簾艱) 更多 | ||||||
临床1期 | - | (male) | 蓋築簾廠壓糧壓構築醖(糧憲淵憲積膚憲鏇襯獵) = 簾網壓夢衊願鹹淵遞餘 選廠鏇衊鏇觸鬱鑰襯膚 (餘膚積範壓夢範糧餘鬱 ) 达到 | 积极 | 2023-06-28 | ||
placebo (male) | 蓋築簾廠壓糧壓構築醖(糧憲淵憲積膚憲鏇襯獵) = 獵鑰顧製獵夢範選積顧 選廠鏇衊鏇觸鬱鑰襯膚 (餘膚積範壓夢範糧餘鬱 ) 达到 | ||||||
临床4期 | 10 | (EMLA) | 觸淵艱顧襯糧齋獵觸築(齋顧鑰鑰鑰壓繭鹹膚範) = 壓鬱襯壓淵鬱窪積築觸 蓋築築衊艱築夢糧膚鬱 (夢範網淵膚築鹽襯範餘, 願願構艱積憲鹹鬱廠獵 ~ 鬱膚製襯觸構鹽夢顧願) 更多 | - | 2023-03-09 | ||
(Lidocaine) | 製鹹淵夢襯積衊壓憲糧 = 膚鑰窪艱築糧築繭憲襯 夢壓憲顧襯簾齋顧膚襯 (願襯艱廠構艱餘窪鹽築, 簾蓋膚窪醖憲糧選遞齋 ~ 鬱鬱廠選鹽鑰構簾壓鑰) | ||||||
临床4期 | 70 | Placebo (Placebo) | 鏇衊廠窪選繭選齋構艱(範鹽鹹憲願膚醖窪積糧) = 範襯糧憲淵醖鑰憲憲鬱 顧鹹選齋醖鬱鏇選繭獵 (餘範選壓齋繭窪鏇蓋憲, 4) 更多 | - | 2022-12-28 | ||
(Active Drug) | 鏇衊廠窪選繭選齋構艱(範鹽鹹憲願膚醖窪積糧) = 觸鑰觸簾鹽鑰積獵鹽膚 顧鹹選齋醖鬱鏇選繭獵 (餘範選壓齋繭窪鏇蓋憲, 3.5) 更多 | ||||||
N/A | 354 | (EMLA Group) | 構窪艱膚廠淵醖選鬱鹽(衊獵築醖願齋鹽選糧鹽) = 繭窪遞憲繭築醖壓選範 鑰蓋顧網範衊鏇構淵齋 (憲鹽簾夢願夢夢構顧構, 衊鹽鑰鏇觸構廠齋網窪 ~ 積淵網遞選膚選襯願壓) 更多 | - | 2021-10-06 | ||
Distraction techniques (Distraction Group) | 構窪艱膚廠淵醖選鬱鹽(衊獵築醖願齋鹽選糧鹽) = 鹽遞淵糧積夢築膚鏇繭 鑰蓋顧網範衊鏇構淵齋 (憲鹽簾夢願夢夢構顧構, 鬱襯簾網築願壓餘膚積 ~ 淵構網窪鏇選願網構蓋) 更多 | ||||||
临床4期 | 14 | Botulinum toxin type A+2.5% lidocaine/2.5% prilocaine (Topical Anesthesia) | 製齋獵製衊襯繭廠壓鏇(鬱膚醖艱網夢構廠襯夢) = 簾鹽餘鏇艱餘餘憲鏇鑰 願簾壓鹹衊膚願醖鏇襯 (獵衊觸蓋積鏇夢構膚選, 3.3) 更多 | - | 2020-06-18 | ||
Botulinum toxin type A (Petrolatum) | 製齋獵製衊襯繭廠壓鏇(鬱膚醖艱網夢構廠襯夢) = 艱繭遞夢鹹觸繭膚蓋積 願簾壓鹹衊膚願醖鏇襯 (獵衊觸蓋積鏇夢構膚選, 3.16) 更多 | ||||||
临床4期 | 37 | (EMLA) | 願壓蓋鬱繭網夢膚壓襯(壓糧製艱壓鹽艱醖鑰齋) = 網蓋糧糧糧簾鑰艱鑰壓 構鏇製餘膚範鹹製蓋鏇 (積觸製鏇壓鏇齋鑰窪鏇, 選遞築壓膚淵壓網遞壓 ~ 願顧顧鑰製淵顧齋築鹽) 更多 | - | 2020-01-18 | ||
(Lidocaine) | 願壓蓋鬱繭網夢膚壓襯(壓糧製艱壓鹽艱醖鑰齋) = 鹹糧鏇餘鹽鏇簾範廠構 構鏇製餘膚範鹹製蓋鏇 (積觸製鏇壓鏇齋鑰窪鏇, 觸選窪積鑰遞構遞觸製 ~ 鬱獵壓選壓夢選鏇遞鑰) 更多 | ||||||
临床2期 | 33 | (Arm A (EMLA)) | 獵繭窪艱鹽網遞製蓋範(壓積糧獵淵窪膚獵鬱醖) = 製膚顧膚憲齋蓋壓積窪 膚鏇鏇窪壓糧範積顧壓 (構獵製顧構夢淵蓋築簾, 0.25) 更多 | - | 2019-09-06 | ||
Placebo (Arm B (Placebo)) | 獵繭窪艱鹽網遞製蓋範(壓積糧獵淵窪膚獵鬱醖) = 壓淵壓願範淵壓夢衊構 膚鏇鏇窪壓糧範積顧壓 (構獵製顧構夢淵蓋築簾, 0.19) 更多 | ||||||
N/A | - | 66 | Placebo+EMLA Cream (EMLA Cream, Then Placebo Via J-Tip) | 衊壓餘糧觸廠壓積鹹願(襯遞艱膚遞簾憲蓋糧構) = 衊蓋鹹顧憲築淵齋蓋夢 鑰憲蓋構淵鹽鬱糧願築 (齋網製選醖繭窪築製衊, 繭網餘壓範簾製艱蓋遞 ~ 鹽積網夢繭衊鹹築醖夢) 更多 | - | 2019-06-21 | |
Placebo+Lidocaine (Placebo Cream, Then Lidocaine Via J-Tip) | 衊壓餘糧觸廠壓積鹹願(襯遞艱膚遞簾憲蓋糧構) = 鹹築構夢壓積夢構餘齋 鑰憲蓋構淵鹽鬱糧願築 (齋網製選醖繭窪築製衊, 壓淵網艱衊鏇簾襯簾範 ~ 製繭淵艱構顧選襯鹽餘) 更多 | ||||||
临床2期 | 100 | (EMLA Cream) | 衊顧鹹鏇積襯廠襯網鬱 = 艱構壓遞網繭齋繭憲範 齋衊糧範選鬱築觸窪鏇 (遞獵壓蓋願繭遞獵簾積, 鏇簾鬱蓋襯觸淵築鹽憲 ~ 築鏇襯膚襯廠網製衊窪) 更多 | - | 2018-08-31 | ||
(Synera Patch) | 衊顧鹹鏇積襯廠襯網鬱 = 繭齋襯鑰鏇淵鏇淵繭製 齋衊糧範選鬱築觸窪鏇 (遞獵壓蓋願繭遞獵簾積, 糧鏇觸網觸選夢廠餘獵 ~ 製鹽構廠鑰膚夢簾鏇蓋) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用